Life Science Investing Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN Rapamycin for Cutaneous Venous Malformations
Life Science Investing Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
Life Science Investing Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D. as Chief Innovation Officer
FPX Nickel Announces Funding Contribution from Natural Resources Canada to Advance the Baptiste Nickel Project
SAGA Metals Expands Radar Ti-V-Fe Project Vision with Preliminary Metallurgical Insights and Major Exploration Milestones
Homerun Resources Inc. Announces Updated Offtake Agreement with Brasil Fotovoltaico for the Supply of High-Quality Solar Glass
